Passamani E R
Circulation. 1980 Dec;62(6 Pt 2):V106-10.
Design features of 17 ongoing clinical trials testing various platelet-active drug regimens in the primary or secondary prevention of coronary or cerebrovascular disease are summarized. The likelihood of detecting biologically important effects given their presence varies widely among the trial; a few have very modest statistical power; others are more robust. The majority of the trials will conclude follow-up and report results within the next several years.